Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

计划入组 39 人 · 首次发布于 2016 年 1 月 12 日

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

计划入组 37 人 · 首次发布于 2016 年 1 月 12 日

Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

计划入组 12 人 · 首次发布于 2022 年 3 月 24 日

AAV2 smCBA based ND4 gene therapy (University of Miami)

AAV2 smCBA based G11778A ND4 gene therapy (University of Miami)

JIUYUAN GENE

Triple-Gene LLC

United States

MOMOTARO-GENE INC.

Japan

LUMEVOQ Gene Therapy Shows Sustained Vision Improvement in LHON Patients After 5 Years

GenSight Biologics Secures French Regulatory Approvals for GS010/LUMEVOQ Gene Therapy in Rare Blindness Disease

GenSight Biologics Secures FDA Authorization for Expanded Access Treatment of Rare Blinding Disease